TORONTO, May 8 /PRNewswire/ - Interface Biologics Inc., Toronto, Ontario, is very pleased to announce the addition of Dr. Robert Schwartz, M.D. to its Advisory Board. Dr. Schwartz is Medical Director at the Minneapolis Heart Institute Foundation, Professor of Medicine at the University of Minnesota and also serves as a Cardiologist at the Minneapolis Heart Institute. He was previously Director at the Center for Applied Vascular Biology and Interventions, Mayo Foundation.
“We were very pleased when Dr. Schwartz agreed to serve on our Advisory Board. His vast knowledge of research topics plus being a practicing cardiologist will be of great value not only to our drug eluting stent program, but also to the company’s entire portfolio of product platforms,” said Rich Sullivan, President & CEO.
Interface Biologics Inc. (IBI) is a privately held biomaterials company located in Toronto, Canada. The company develops and markets cutting edge polymer technologies that are programmed at the nano level for the combination medical device marketplace.
Interface Biologics Inc.
CONTACT: Mark Steedman, Director, Business Development, (416) 673-8158, orwww.interfacebiologics.com
